# A PHARMACOVIGILANCE STUDY ON MEDICINE USED IN PREGNANCY

UNNATI KUNDAP[1], PRITAM SALOKHE[2], DR. NILESH CHOUGHULE[3], ANKITA BHOSALE[4], PRANALI LAD[5]

[1]Student of Ashokrao Mane institute of Pharmacy, Ambap, Kolhapur416112, Maharashtra, India.

[2]Assistant Professor of Ashokrao Mane institute of Pharmacy, Ambap, Kolhapur416112, Maharashtra, India.

[3]Principle of Ashokrao Mane institute of Pharmacy, Ambap, Kolhapur416112, Maharashtra, India.

[4]Student of Ashokrao Mane institute of Pharmacy, Ambap, Kolhapur416112, Maharashtra, India.

[5]Student of Ashokrao Mane institute of Pharmacy, Ambap, Kolhapur416112

Address for Correspondence Author -Unnati Kundap.

A/P- Vadgaon (J.S) , Tal- Khatav, Dist- Satara 415512, Maharashtra, India.

unnatikundap@gmail.

**ABSTRACT:**

Pharmacovigilance in the Pregnancy is necessary to protect the mother's and the unborn child'shealth. This study underscores the significance of monitoring adverse drug reactions (ADRs) associated with med ications commonly prescribed during pregnancy. Medications such as magnesium sulfate, methyldopa, insulin, ceftriax one, and antiretroviral therapy (ART) play a crucial role in managing conditions like preeclampsia, hypertension, diabet es, bacterial infections, and HIV, respectively. However, these drugs are also linked to higher risks of ADRs, including somnolence, liver dysfunction, hypoglycemia, allergic reactions, and liver toxicity. Effective pharmacovigilance involv es meticulous data collection, quality assessment, and strict adherence to regulatory guidelines to mitigate these risks. E ducating healthcare providers and pregnant women about potential ADRs and ensuring informed decisionmaking are vit

al components of this process. This study highlights the need for ongoing monitoring and research to improve the safety of medication use during pregnancy.

**KEYWORDS:** Pharmacovigilance, Pregnancy, Adverse Drug Reactions, Data Collection, Monitoring

## I. INTRODUCTION

**Definition of Pharmacovigilance:**

Pharmacovigilance is the science and activities concerned with the detection, assessment, understanding, and prevention of adverse effects or any other drugrelated problems. The term is derived from the Greek word "pharmakon" (meaning drug) and the Latin word "vigilare" (meaning to keep watch). It is a vital aspect of public health and patient safety, ensu ring that medicinal products are used safely and effectively throughout their lifecycle.1

**Importance of Pharmacovigilance in Pregnancy:**

Pregnancy is a distinct physiological state while.using medications during pregnancy needs to be done with extra caution .

The maternal body undergoes significant changes in metabolism, hormone levels, and organ function, which can alter th e pharmacokinetics and pharmacodynamics of drugs. This makes the monitoring of drug safety particularly crucial duri ng pregnancy.

Pharmacovigilance in pregnancy is essential for several reasons:

1. **Protecting Maternal and Fetal Health**: Ensuring that medications used during pregnancy do not harm the mo ther or the developing fetus is of utmost importance. Adverse drug reactions (ADRs) can lead to majorhealth p roblems, including birth defects, miscarriage, and maternal morbidity.2
2. **Managing Chronic Conditions**: Many women require continued medication during pregnancy for chronic co nditions such as hypertension, diabetes, and HIV. Effective pharmacovigilance ensures that these medications are safe for use during pregnancy and helps manage any potential risks.3
3. **Guiding Clinical Practice**: Data collected through pharmacovigilance can inform clinical guidelines and best practices for prescribing medications during pregnancy. This helps healthcare providers make informed decisio ns and provide the best care possible4

## II. ADVERSE DRUG REACTIONS (ADRS) IN PREGNANCY

**Types of ADRs in Pregnancy**

ADRs can vary widely, affecting different organ systems and leading to a range of symptoms. Here are some c ommon types:

1. **Teratogenic Effects**: These are birth defects caused by exposure to certain drugs during fetal development. Te ratogenic effects can include:
    - **Congenital heart defects**: Abnormalities in the structure of the heart present from birth.
    - **Neural tube defects**: Defects in the development of the brain, spine, or spinal cord, such as spina bifi da.
    - **Limb malformations**: Abnormalities in the formation of arms or legs.5

2. **Hypersensitivity Reactions**: These are immune system reactions that can range from mild to severe. Example s include:
    - **Rashes and itching**: Common allergic reactions to medications.
    - **Anaphylaxis**: A severe, potentially life-threatening allergic reaction that can occur rapidly.6
3. **Metabolic and Endocrine Effects**: Medications can interfere with normal metabolic processes and hormone f unction, leading to:
    - **Hypoglycemia or hyperglycemia**: Abnormal blood sugar levels, particularly important in managing diabetes during pregnancy.
    - **Thyroid dysfunction**: Abnormal thyroid hormone levels, which can affect both the mother and fetus.
4. **Hepatotoxicity**: Some drugs can cause liver damage, leading to:
    - **Elevated liver enzymes**: Indicators of liver injury or stress.
    - **Jaundice**: Yellowing of the skin and eyes due to increased bilirubin levels.7
5. **Neurological Effects**: Medications can affect the nervous system, causing:
    - **Somnolence**: Excessive drowsiness or sleepiness.
    - **Seizures**: Uncontrolled electrical activity in the brain, which can be dangerous for both mother and fet us.8,9

**III. Common Medications Associated with ADRs in Pregnancy**

Several medications are commonly used during pregnancy to manage various conditions, and each comes with potential ADRs:

1. **Magnesium Sulfate**:
    - **Uses**: Primarily used to prevent seizures in women with preeclampsia and eclampsia, and as a tocolyti c to delay preterm labor.
    - **ADRs**: Respiratory depression, hypotension, hyporeflexia, and flushing. Overdose can lead to toxicity , requiring immediate medical intervention.10
2. **Methyldopa**:
    - **Uses**: An antihypertensive drug used to manage high blood pressure in pregnant women.
    - **ADRs**: Can cause dizziness, fatigue, dry mouth, and liver dysfunction. Rarely, it can cause severe he molytic anemia.11,12
3. **Insulin**:
    - **Uses**: Essential for managing gestational diabetes or pre-existing diabetes during pregnancy.
    - **ADRs**: Hypoglycemia is the primary concern, which can occur if the insulin dose is not adjusted prop erly. Symptoms include shakiness, sweating, and confusion.
4. **Ceftriaxone**:
    - **Uses**: A broad-spectrum antibiotic used to treat bacterial infections during pregnancy.
    - **ADRs**: Allergic reactions, gastrointestinal disturbances like diarrhea, and potential for causing antibio tic-associated colitis.
5. **Antiretroviral Therapy (ART)**:
    - **Uses**: Used to manage HIV infection in pregnant women and prevent mother-to-child transmission.
    - **ADRs**: Can include liver toxicity, gastrointestinal issues, and metabolic disturbances like lipodystroph y and insulin resistance.13,14

A significant rate of long-term therapy during pregnancy is indicated by the fact that 25% of the medications were taken during the entire pregnancy. Drug use was higher in the first trimester (85.4%) compared to the second (44.1%) and third (36.5%) trimesters. Our statistics are with the views of other writers who have observed a rise in the number of pregnant women prescribed medications and the number of exposed women overall. 15

## IV. MONITORING OF THE SAFETY OF DRUG USE DURING PREGNANCY:

Pharmacovigilance is particularly interested in the monitoring of drug use safety during pregnancy (PV). Pregnancy and drug use provide a special case because the pregnant woman's unborn child may experience adverse drug reactions as well. When a medicine is introduced to the market, little is known about these possible dangers. For ethical reasons, pregnant women are not allowed to participate in pre-marketing trials unless the medication is meant to be taken throughout pregnancy. Furthermore, the predictive power of animal studies to determine the potential teratogenicity of a medication in humans is limited. Consequently, the sad truth is that most teratogenic effects are discovered only after a medication has been approved for sale and taken by expectant mothers.16, 17

• Data collection

There are limited guidelines for how to collect data to assess the safety of medications during pregnancy. However, there are expert opinions on what core data elements should be collected to improve the speed of providing high-quality evidence.

PV centers primarily employ two techniques for gathering data: cohort event monitoring and spontaneous reporting. The same applies to gathering information about the safety of drug use during pregnancy, however there will be certain changes that are covered in the two following sections. as both methods gives their distinct benefits, both approaches can be viewed as complimentary to one another. 18,19,20

- **Cohort event monitoring in pregnancy**

Data on the safety of drug use can be actively gathered by cohort event monitoring. This approach is frequently utilized in pregnancy and is known as a pregnancy (exposure) registry. Pregnancies exposed to a particular drug or class of pharmaceuticals (e.g., anti-epileptic or anti-retroviral treatments), a particular maternal condition (with or without drug exposures), or the whole pregnant population may comprise a cohort. As soon as possible during pregnancy, cases are enrolled, and they may be constantly watched until the child reaches a specific age. It is possible to record both short-term and long-term effects, depending on how long the monitoring period was.

One benefit of cohort event monitoring is that cases are recorded prospectively before any pregnancy outcomes are known, which helps to prevent selection bias. The inclusion of unexposed pregnancies alongside drug-exposed pregnancies depends on the setting.

In contrast to spontaneous reporting, if there are enough instances, cohort event monitoring may make it possible to determine the prevalence of unfavorable pregnancy outcomes after drug and/or disease exposures.

- Medication exposure

Pregnancy outcomes can be impacted by drugs even if they do not cross the placenta. The amount of oxygen and nutrients that reach the fetus can be decreased, for instance, by medications that produce vasoconstriction or hypotension in the placenta.

- Medication history

Medication history-wide association studies can help generate hypotheses for post-market drug surveillance. These studies can use data from primary medical care encounters for pregnant patients.

- Demographic Surveillance System

The Demographic Surveillance System (DSS) is a platform that can be used to establish a pharmacovigilance system for pregnancy. The DSS can help identify vital events such as pregnancy, birth, and death.

- Clinical trials

Clinical trials frequently do not include pregnant women, which might result in a lack of knowledge regarding the possible hazards and efficacy of medications.

The goal of PV centers with teratology and pregnant PV expertise is to actively contribute to the establishment of national clinical practice guidelines. This assures that medical professionals will always have timely access to relevant details regarding pregnancy safety: when giving medication to women who are pregnant or who are of reproductive age 21, 22, 23, 24,

## V.ROLE OF HEALTHCARE PROVIDERS IN PHARMACOVIGILANCE STUDIES ON PREGNANCY MEDICATION

Healthcare providers play a crucial role in pharmacovigilance studies related to pregnancy medication. Their respo nsibilities ensure the safety and efficacy of medications used during pregnancy, ultimately protecting both maternal and fetal health. Here's a detailed exploration of their key roles:

**1. Reporting Adverse Drug Reactions (ADRs)**

Healthcare providers are on the frontline when it comes to detecting and reporting ADRs. They:

- **Identify ADRs**: Recognize and document adverse reactions in pregnant patients.
- **Report ADRs**: Submit detailed reports to national pharmacovigilance centers such as the FDA's Adverse Eve nt Reporting System (FAERS) or the WHO's VigiBase.

**Example**: A pregnant woman taking insulin for gestational diabetes experiences hypoglycemia. The healthcare pro vider reports this incident to the pharmacovigilance center, contributing to the database of known ADRs.

**2. Active Surveillance**

Providers engage in active surveillance, which involves:

- **Monitoring**: Systematically tracking the effects of medications through registries and electronic health records (EHRs).
- **Follow-up**: Conducting follow-up appointments to assess ongoing medication safety.

**Example**: Participating in a pregnancy exposure registry for antiepileptic drugs (AEDs) to monitor their effects on both mothers and babies.

**3. Educating Patients**

Healthcare providers play a vitalrole in educating pregnant women about the medications they are taking. They:

- **Inform**: Explain potential ADRs and the importance of reporting any side effects.
- **Counsel**: Provide guidance on safe medication practices and lifestyle adjustments.

**Example**: A provider educates a pregnant woman with HIV about the potential ADRs of antiretroviral therapy (AR T) and the importance of adherence to prevent mother-to-child transmission.

**4. Conducting Post-Authorization Studies**

Providers may be involved in studies conducted after a drug has been approved, such as:

- **Collecting Data**: Gathering real-world data on the safety and efficacy of medications.
- **Analyzing Results**: Working with researchers to analyze data and publish findings.

**Example**: Participating in a post-
marketing study of methyldopa to gather additional data on its safety profile during pregnancy.

**5. Risk-Benefit Analysis**

Healthcare providers conduct risk-benefit analyses to:

- **Evaluate**: Assess the potential risks and benefits of medications.
- **Decide**: Make well-informed choices when recommending drugs to expectant patients.
- **Example**: Considering the risk-
benefit profile of prescribing ceftriaxone for a bacterial infection, balancing the need to treat the infection with the potential for allergic reactions.

**6. Collaborating with Pharmacovigilance Teams**

Providers collaborate with pharmacovigilance teams to:

- **Share Data**: Provide valuable clinical data that helps in continuous monitoring of drug safety.
- **Develop Guidelines**: Contribute to the creation of clinical guidelines and best practices.

**Example**: Working with a pharmacovigilance team to update clinical guidelines for managing preeclampsia with m agnesium sulfate, based on the latest safety data.

**7. Participating in Research Initiatives**

Healthcare providers contribute to research initiatives aimed at enhancing drug safety. They:

- **Conduct Studies**: Engage in clinical trials and observational studies.
- **Publish Findings**: Share results with the broader medical community to inform practice.

**Example**: Conducting a study on the long-
term effects of insulin use during pregnancy, and publishing the findings in a medical journal.

By fulfilling these roles, healthcare providers ensure that pregnant women receive safe and effective care, contribut ing to the overall success of pharmacovigilance programs. Their involvement is essential for the continuous improv ement of medication safety during pregnancy. 24,25,26,27,28,29,30

## VI.FUTURE PERSPECTIVES OF PHARMACOVIGILANCE ON PREGNANCY MEDICINES

**1. Inclusion of Pregnant Women in Clinical Trials**

Historically, pregnant women have been excluded from clinical trials, leading to a lack of data on the safety an d efficacy of medications during pregnancy. Including pregnant women in clinical trials is crucial to gather mo

re comprehensive data on drug interactions, dosages, and potential ADRs. This shift will require developing et hical guidelines and ensuring informed consent, protecting both the mother and the fetus.

**2. Advanced Data Analytics**

The use of big data and advanced analytics will enhance the detection and analysis of ADRs in pregnant wome n. Machine learning and artificial intelligence (AI) can process large volumes of data from various sources, ide ntifying patterns and predicting potential risks faster and more accurately than traditional methods. This approa ch will improve the monitoring of drug safety and efficacy in real-time.

**3. Personalized Medicine**

Tailoring medication regimens based on individual genetic profiles and specific health conditions will improve the safety and efficacy of pregnancy medicines. Pharmacogenomics can help determine how different women metabolize and respond to medications, allowing for more precise dosing and reducing the risk of ADRs. Perso nalized medicine will lead to better outcomes for both mothers and their babies.

**4. Global Collaboration**

Strengthening international collaboration and data sharing will improve the monitoring and management of A DRs in pregnancy. Harmonizing regulatory guidelines and practices will ensure consistent safety standards acr oss different countries. Initiatives like the International Conference on Harmonisation (ICH) can facilitate coop eration between regulatory bodies, healthcare providers, and researchers.

**5. Patient-Centered Approaches**

Engaging pregnant women in the decision-
making process and providing them with comprehensive information about medication risks and benefits will e nhance patient safety and satisfaction. This approach involves shared decision-
making, where patients and healthcare providers work together to choose the best treatment options. Educating women about the importance of reporting ADRs will also contribute to better pharmacovigilance.

**6. Regulatory Innovations**

Regulatory agencies will continue to develop and refine guidelines for the safe use of medications during preg nancy. The European Medicines Agency (EMA), FDA, and other regulatory bodies are working on new standa rds to address the unique challenges of pregnancy pharmacovigilance. These innovations will include more stri ngent requirements for post-marketing surveillance and the inclusion of pregnancy-
specific information in drug labels.

**7. Education and Training**

Ongoing education and training for healthcare providers will ensure they are equipped to recognize, report, and manage ADRs in pregnant patients. This includes continuous professional development programs, workshops, and online courses. Improving knowledge and awareness among healthcare professionals will enhance the ove rall quality of care for pregnant women.

**8. Technological Advancements**

The integration of new technologies, such as electronic health records (EHRs) and mobile health applications, will facilitate real-
time monitoring and reporting of ADRs. EHRs can provide a comprehensive view of a patient's medical histor y, helping to identify potential drug interactions and ADRs. Mobile health applications can enable pregnant wo men to report side effects and receive timely advice from healthcare providers.31,32,33,34,35

## CONCLUSION

In summary, pharmacovigilance is a vital component in ensuring the safety of medications, especially during p regnancy. The unique physiological changes and increased vulnerability of both the mother and fetus make it i mperative to monitor and assess adverse drug reactions (ADRs) meticulously. The future of pharmacovigilance in pregnancy medicines is promising, with advancements in data analytics, personalized medicine, and global collaboration set to enhance drug safety. Including pregnant women in clinical trials, leveraging advanced tech nologies, and emphasizing patient-

centered approaches will lead to more comprehensive safety data and better healthcare outcomes. Continuous e ducation and training for healthcare providers, along with regulatory innovations, will further support the safe use of medications during pregnancy. Ultimately, the collaborative efforts of regulatory bodies, healthcare pro viders, researchers, and patients will ensure the optimal safety and efficacy of pregnancy medications, safeguar ding maternal and fetal health.

## REFERENCES

1. Schafer, I.; Oltrogge, J.H.; Nestoriuc, Y.; Warren, C.V.; Brassen, S.; Blattner, M.; Luhmann, D.; Tinnermann, A.; Scherer, M.; Buchel, C. Expectations and Prior Experiences Associated with Adverse Effects of COVID-19 Vaccination. *JAMA Netw. Open* **2023**, *6*, e234732.

2. Yi, S.; Cagkan Inkaya, A.; Jo, J.; Sitaresmi, M.N. Adverse Events Following Immunization of COVID-19 Vaccine among Children Aged 6–11 Years. *Front. Public Health* **2021**, *10*, 999354.

3. Clair, L.A.S.; Chaulagain, S.; Klein, S.L.; Benn, C.S.; Flanagan, K.L. Sex-Differential and Non-Specific Effects of Vaccines Over the Life Course. *Curr. Top. Microbiol. Immunol.* **2023**, *441*, 225.

4. Klein, S.L.; Jedlicka, A.; Pekosz, A. The Xs and Y of Immune Responses to Viral Vaccines. *Lancet Infect. Dis.* **2010**, *10*, 338–349

5. A.A. Mitchell *et al.* Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008

6. Jain S, Anand S, Aherwar R. High risk scoring for prediction of pregnancy outcome: a prospective study. *Int J Reprod Contraception, Obstet Gynecol.* 2014;**3**:516–522. doi: 10.5455/2320-1770.ijrcog20140910

7. Kim, J. H., & Scialli, A. R. (2011). Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicological sciences, 122(1), 1-6.

8. Kozer, E., Nikfar, S., Costei, A., Boskovic, R., Nulman, I., & Koren, G. (2002). Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. American journal of obstetrics and gynecology, 187(6), 1623-1630.

9. Nezvalová-Henriksen, K., Wood, M., Spigset, O., & Nordeng, H. (2016). Association of prenatal ibuprofen exposure with birth weight and gestational age: A population-based sibling study. PloS one, 11(12), e0166971.

10. Soh MC, Nelson-Piercy C. High-risk pregnancy and the rheumatologist. Rheumatology (Oxford). 2015;54:572–87.

11. Hernández-Hernández DC, Vargas-Rivera MJ, Nava-Ocampo AA, Palma-Aguirre JA, Sumano-López H. Drug therapy and adverse drug reactions to terbutaline in obstetric patients: a prospective cohort study in hospitalized women. *BMC Pregnancy Childbirth.* 2002;**2**:1–6. doi: 10.1186/1471-2393-2-3

12. Koren G, Pariente G. Pregnancy-associated changes in pharmacokinetics and their clinical implications. *Pharm Res.* 2018;**35**(3):61. doi: 10.1007/s11095-018-2352-2.

13. Athukorala C, Rumbold AR, Willson KJ, Crowther CA. The risk of adverse pregnancy outcomes in women who are overweight or obese BMC Pregnancy Childbirth. 2010;10 doi: 10.1186/1471-2393-10-56

14. Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-counter medications during pregnancy Am J Obstet Gynecol. 2005;193:771–7

15. Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf. 2006;15:546 – 54.

16. Krause G, Borchert M, Benzler J, Heinmüller R, Kaba I, Savadogo M, et al. Rationality of drug prescriptions in rural health centres in Burkina Faso. Health Policy Plan. 1999; 14:291–8.

17. Australian Government Department of Health. Australian categorisation system for prescribing medicines in pregnancy. Accessed 22 Sep 2017.

18. Banhidy F, Lowry RB, Czeizel AE. Risk and benefit of drug use during pregnancy. *Int J Med Sci.* 2005;2:100–6.

19. Ravindu Gunatilake, MD, Valley Perinatal Services; Avinash S. Patil, MD, University of Arizona College of Medicine, Reviewed/Revised Mar 2021| Modified Sep 2022 [

20. Nanavati MS. Obstetrics Handbook for Maternal Health. 1st ed. Mumbai: Niche Laboratories Ltd; 1994. [19] Briggs GG. Drug effects on the fetus and breastfed infants. Clin Obstet Gynaecol. 2002;45:6–21.

21. World Health Organization . *A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis: enhancing the safety of the TB patient.* Geneva: WHO; 2012.

22. Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. Uppsala Monitoring Centre. 2012. Accessed 3 March 2015

23. Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. *Drug Saf.* 2013;36(2):75–81. doi: 10.1007/s40264-012-0014-6

24.Titaley CR, Dibley MJ, Roberts CL, Hall J, Agho K. Iron and folic acid supplements and reduced early neonatal deaths in Indonesia. Bull World Health Organ. 2010;88:500–508.

25. van Andel T, Carvalheiro LG. Why urban citizens in developing countries use traditional medicines: the case of suriname. eCAM. 2013;2013:687197.

26. Welfare MoHaS . District Health Profile 2010. MOH: Tanzania; 2011.

27. Shabani J, Lutambi AM, Mwakalinga V, Masanja H. Clustering of under-five mortality in Rufiji health and demographic surveillance system in rural Tanzania. Global Health Action. 2010;3:10. doi: 10.3402/gha.v3i0.5264.

28. US Food and Drug Administration . Drug.com. 2013. FDA pregnancy categories. [

29. Welfare TMoHaS . Standard Treatment Guidelines and the National Essential Medicines List for Mainland Tanzania. 3. Tanzania: MOH; 2007.

30. Mehta U, Clerk C, Allen E, Yore M, Sevene E, Singlovic J, Petzold M, Mangiaterra V, Elefant E, Sullivan FM, Holmes LB, Gomes M. Protocol for a drugs exposure pregnancy registry for implementation in resource-limited settings. BMC Pregnancy Childbirth. 2012;12:89. doi: 10.1186/1471-2393-12-89.

31. Hama R. The Mechanisms of Adverse Reactions to Oseltamivir: Part II. Delayed type reactions. Clinical Microbiology. 2015; 4:224-228.

32. Huerta-Sanchez OM. Implementation of a Robust Pharmacovigilance Method for Filgrastim Non-Innovator Products in Cancer Patients in Routine Clinical Practice Complying With Mexican Regulations for Incomparable. Journal of Pharmacovigilance. 2015; 3:174-176.

33. Kalaiselvan V, Prasad T, Bisht A, Singh S, Singh GN. adverse drug reactions reporting culture in pharmacovigilance programme of India. Indian Journal of Medical Research. 2014; 5:114-117. 19.

34. Kaur I. Effective Reporting by Pharmacist in Pharmacovigilance Programme of India. Advance in Pharmacoepidemiology, Drug Safety. 2015; 4:197-199. 20.

35. Kowalski CJ, Mrdjenovich AJ. Pharmacovigilance Observed: Why Watchful Waiting will Work. Journal of Clinical Diagnosis. 2015; 3:114-115.